MYC rearrangements with non-IG partners are observed in about 3% of B-cell non-Hodgkin's lymphomas (NHL). Few studies have been dedicated to this subject until our recent paper 1 in which we reported the FISH mapping of 17 MYC-non IG translocations along with the molecular characterization of t(8;9)(q24;p13) translocations identified in two patients. The level of MYC transcript, determined in seven cases, was found to be increased as compared to that of samples without 8q24 rearrangement. Among these 7 cases, two t(3;8)(q27;q24) were detected in patients with germinal center-type diffuse large B-cell lymphoma (GC-DLBCL), UPN602 and UPN1168 (cases no.1 and 2 of this study). FISH mapping of the corresponding breakpoint regions on chromosome 8 showed that they were located 140-370 kb downstream from MYC. On chromosome 3, breakpoints were located in a 65 kb region encompassing BCL6 for case no.1, and 89-200 kb 5 0 from BCL6 exon 1 for case no. 2. In the present study, sequencing of the genomic breakpoints was performed by chromosome walking combined with long-distance PCR (Supplementary methods and Supplementary Figure 1) .
In case no. 1, sequence analysis showed that the chromosome 8 breakpoint was located 196 kb 3 0 from MYC and 10 kb from the transcriptional unit TMEM75, in an Alu sequence (Figures 1a  and 2 ) whereas the chromosome 3 breakpoint was located 5.3 kb upstream BCL6 exon 1 (Figure 1b) . Comparison of the sequences of the two derivatives chromosomes with chromosome 3 and 8 germline sequences showed a 77-82 bp deletion from chromosome 8 along with a 162-167 bp duplication of chromosome 3 sequence at the breakpoint (Figure 2 ). The translocation of the TMEM75 locus 15 kb upstream BCL6 prompted us to verify for possible TMEM75-BCL6 fusion transcripts but results were negative. 
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In case no. 2, chromosome 8 breakpoint was located 369 kb downstream from MYC in a region containing LTR/MaLR-type repetitive sequences (Figures 1b and 2 ). On chromosome 3, it was located 197 kb 5 0 from BCL6, in the vicinity of the BCL6 alternative breakpoint region (ABR). 2 Breakpoints could not be defined accurately due to the presence of overlapping nucleotides from chromosomes 3 and 8 sequences. A mutation (A-G transition) was observed at location 189 143 610, together with a possible mutation (G-A transition) at location 189 143 615. In both cases, the breakpoint was within or in close proximity to a RGYW/WRCY motif.
The cytogenetic pellet of a third patient with a t(3;8)(q27;q24) was available for whom a conventional and molecular cytogenetics study could be performed. Clinical and cytogenetic data are presented in Supplementary Tables 1, 2, and Supplementary Figure 2 . As in cases no.1 and 2, it was a GC-DLBCL, with a t(14;18)(q32;q21) translocation. Breakpoint localization was refined by chromosome walking using directly labeled BACs probes. For each chromosome, a BAC probe remaining on the chromosome, and a split probe were identified ( Figure 1 and Supplementary Figure 3) . The last step was performed by indirect FISH with 12-14 kb probes 3056O22-TEL and 211G3-TEL, prepared by PCR and digoxigenin-or biotinlabeled (primers list in Supplementary Table 3 ). This last experiment allowed us to localize the chromosome 8 breakpoint in a 14 kb region, 25 kb downstream from MYC and close to the breakpoint of a t(2;8)(p11;q24) translocation (Genbank accession no. X05930). On chromosome 3, it was in a 17 kb region, 7 kb upstream BCL6 (Figure 1 ).
In the 3 cases of this study, chromosome 8 breakpoints were distant from about 150 kb from each other. The sequence of another t(3;8)(q27;q24) was recently deposited (Genbank accession no. AB303308), in which the MYC breakpoint was inside MYC exon3, close to the 3 0 end in the untranslated region. This result and ours confirm the absence of clustering of MYC breakpoints observed previously for IG/MYC translocations. On chromosome 3, among the three translocations of this study, one was located close to the ABR region, and two were located 5-24 kb upstream from BCL6 first exon, as in sequence AB303308.
These translocations probably represent secondary events consecutive to the t(14;18)(q32;q21), wich occurred in the germinal center (GC) and could be related to the transformation of follicular lymphoma into higher grade lymphoma. Somatic hypermutation (SHM) and class-switch recombination (CSR) are IG genes targeting processes occurring in GC and mediated by the activation-induced deaminase enzyme (AID). Like IG genes, BCL6 is a target for SHM in B-cells. Mutations are clustered in the 5 0 non coding region in the major mutation cluster (MMC), 3 included in the major translocation cluster (MTC), thus rendering the mutation targeted region susceptible to subsequent translocations. In cases no. 1 and 2, analysis of the junction sequence revealed one deletion and one duplication. In case no. 2, chromosome 3 was highly mutated in the MMC (see below) and one point mutation was found close to the breakpoint. These observations, together with the location of breakpoints within the AID targeted RGYW/WRCY motifs are in favor of a mismatch repair following a SHM or CSR activation in Letters to the Editor the GC. Conversely, the existence of breakpoints distant from BCL6 (i.e. ABR) suggests that mutations could occur far from BCL6, as observed in case no. 2, but published data concerning this region are too scarce to conclude. To analyze the effect of the translocation on BCL6 gene expression, we examined BCL6 mRNA levels in case no. 1 and 2 by real-time quantitative RT-PCR as previously described. 4 Measurements were performed in hexaplicate for both cases. 11 GC-type DLBCL without 3q27 rearrangement were used as controls and measured in duplicate. Among them, seven cases had a t(14;18)(q32;q21). Low sample size was taken into account for calculations. Relative expression levels (mean [95% confidence interval]) for controls and cases no. 1 and 2 were 0.824 (0.450-1.198), 1.997 (1.671-2.324), and 2.218 (1.817-2.619) respectively. These results suggest that BCL6 hyperexpression could be a consequence of the translocation. As it is known that BCL6 is the target of somatic hypermutations process with possible effect on its expression, 5 we also investigated the BCL6 mutational status in cases no.1 and 2. Mutations were analyzed in the region encompassing exon 1 and the MMC. Primers used for amplification were 5 0 -GCAGGCCATACCATCGTC-3 0 and 5 0 -TAGACACGATACTT CATCTCAT-3 0 Marked difference were noted between the two cases (Table 1) : only two point mutations were detected in case no.1, outside the ES and IS negative regulatory regions previously described in BCL6 exon 1 and intron 1, respectively. 5 In case no. 2, 32 mutations were found. Among them, five mutations were located inside ES or IS regions.
Breakpoints of the majority of BCL6 translocations are located in the first intron, leading to a deregulated BCL6 expression driven by the promoter of the partner gene. In all three cases of this study the BCL6 gene remained intact, as in few cases of 
Table 1
Description of the BCL6 mutations Case Mutations A90C, C119T, T120A,  G122C, T131A, A185G, A199T, T270C, T278A, T312A,  DEL T357, INSER C421, G422A, T427C, G431A, C432T,  G437A, A455C, C457G, T482C, T493A, G498A, C507G,  T517G, C519T, T570C , C604T, G611A, A717T
In order to facilitate comparison of observed mutations with previously published data, the BCL6 region is numbered as described by Lossos and Levy. 3 Negative numbering indicates nucleotides located upstream this region. Bold underlined and bold, mutations located in the ES and IS BCL6 negative regulatory regions, respectively.
previously described BCL6/IG translocations with a breakpoint in the 5 0 UTR of BCL6, or in the distant ABR. 2, 6 Thus, in our cases BCL6 deregulation can not be explained by promoter substitution. In case no. 2 the inactivation of BCL6 negative autoregulation sites by mutations can be hypothesized, but in case no.1, for which no mutation was found inside these regions, the most reliable hypothesis involves cis-acting elements provided by the partner sequences. The expression of TMEM75, the closest locus brought by the translocation was investigated. The transcript was detected, at a level which did not differ significantly from the mean level of the 11 previous controls. Thus, the activation of BCL6 by TMEM75 regulating sequences remains possible, but the effects of more distant regions can not be precluded. Indeed, it was demonstrated that enhancers, defined as position and orientation independent activators of transcription, can exert regulating effects several hundred kilobases from targets by DNA folding, thus bringing together enhancer and the target. 7 Regarding the pathophysiological role of the t(3;8), several hypotheses can be raised as: (i) BCL6 expression was significantly increased as compared to controls although the effects of mutations located in negatively regulating region could also explain the gene overexpression; (ii) we have shown previously that, in these cases MYC transcript was also overexpressed; (iii) the formation of MYC-BCL6 complexes at the protein level has been reported, 8 with an effect on MYC halflife, suppression of the synthesis of the p21 CIP cell cycle arrest gene, and inhibition of BCL6 acetylation. Therefore, the synergistic effect of MYC and BCL6 could explain the survival and clonal selection of a t(3;8) carrying cell in lymphoma progression. 1 
